Editor's note

This ExpertREACT article was originally published on 7 November 2011. Financial results and market positions described reflect the state of knowledge at that date.

Industry resilience without H1N1

According to VacZine Analytics' analysis, the major vaccine players sold approximately $6.7bn in Q3 2011 and $15.5bn for the year so far. By comparison with the same three quarters of 2010, which contained approximately $3.5bn in H1N1 monovalent vaccine sales, the industry's underlying resilience was clear. On a reported basis the industry appeared to be maintaining continued underlying growth despite the pandemic revenue shortfall. Provision of vaccines was being driven increasingly by economics as well as medical need, with government austerity programmes a recurring theme.

In reported dollar terms GSK sold $1.83bn (£1,142m) in Q3, with underlying vaccine sales excluding pandemic flu growing by 21%. The bivalent HPV vaccine Cervarix was a principal growth driver, benefiting from Japan's national immunisation programme (NIP) - Cervarix was close to doubling its 2010 sales of $375m, although most growth was attributable to a one-time five-cohort catch-up programme. The US ACIP's recent vote to expand HPV vaccination to adolescent boys and low coverage rates (~30% for all three doses in teenage girls) suggested Cervarix still had further global potential. Rotarix grew 49% in the first nine months of 2011, recovering fully post the PCV-1 episode of 2010.

Q3 2011 industry sales
$6.7bn
Year-to-date total of $15.5bn vs $16.9bn in same period 2010 (which included $3.5bn H1N1 pandemic vaccine sales)

Sanofi and the battle for influenza differentiation

Sanofi Pasteur reported Q3 2011 sales of €1,343m, with strong seasonal flu vaccine sales of €602m - 48% of the total from the US market. Sanofi's strategy to differentiate its influenza franchise faced important milestones: Fluzone High Dose (HD) and Intradermal (ID) were being closely monitored for US performance, and the company's quadrivalent influenza strategy had its first predicted US filing expected the following year. With increasing entrants into influenza vaccine supply, and GSK advancing its own QIV, differentiation was becoming an urgent strategic imperative for Sanofi's dominant flu franchise.